Trial document

This study has been imported from without additional data checks.
drksid header


Trial Description

start of 1:1-Block title


An Open-label, Multi-center Dose Escalation Phase I Study to Investigate the Safety and Tolerability of a Continuous Infusion of the Bispecific T-cell Engager (BiTE) MT110 in Locally Advanced, Recurrent or Metastatic Solid Tumors Which Commonly Express EpCAM and Are Not Amenable to Curative Treatment

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

This phase I dose escalation study is intended to define the safety, tolerability and
maximal tolerable dose (MTD) of MT110 in patients with advanced solid tumors.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

MT110 is a bispecific (anti-EpCAM x anti-CD3) T-cell engager (BiTE) designed to link EpCAM
(epithelial cell adhesion molecule) expressing cells and T-cells resulting in T-cell
activation and a cytotoxic T-cell response against EpCAM+ cells. In vitro and ex-vivo data
indicate that EpCAM+ tumor cell lines are sensitive to MT110 mediated cytotoxicity.
Furthermore, data from in-vivo experiments with both MT110 and a mouse surrogate molecule
(muS110) have confirmed the activity of these molecules in inhibiting the formation of
metastases but also against established tumors. In vitro and ex-vivo data suggest that a
prolonged presence of the drug in target tissues may result in significant T-cell
recruitment, activation and expansion to/in target tissues, potentially resulting in
substantial anti-tumor activity in man.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00004094
  •   2012/11/29
  •   2008/03/07
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2007-004437-42 
  •   NCT00635596  (
  •   MT110-101  (Micromet GmbH)
  •   EUDRACT No: 2007-004437-42 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Solid Tumors
  •   C00-C75 -  Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissue
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Biological: MT110
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   I
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Overall frequency and intensity of adverse events (AEs) (clinical symptoms, laboratory abnormalities, serious adverse events [SAEs] and dose-limiting toxicities); time frame: one or more treatment cycles

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Pharmacokinetics of MT110; T-cell counts, kinetics, and activation status; Serum cytokine concentrations; Immunogenicity; Anti-tumor activity; Other progressive disease (PD) parameters; time frame: one or more treatment cycles

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   [---]*
  •   2008/03/31
  •   70
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

1. Locally advanced, recurrent or metastatic solid tumors known to widely express EpCAM
and proven histology of the following entities:

- Adenocarcinoma of the lung

- Small cell lung cancer (SCLC)

- Gastric cancer or adenocarcinoma of gastro-esophageal junction

- Colorectal cancer (CRC)

- Hormone-refractory prostate cancer (HRPC)

- Breast cancer

- Ovarian cancer

Patients must not be amenable to curative therapy. Patients should have exhausted or
declined standard therapeutic options and previous therapies should have included at
least one course of chemotherapy.

2. Non-measurable disease or at least one measurable tumor lesion as per RECIST criteria

3. Age >/= 18 years

4. ECOG performance status </= 2

5. Life expectancy of at least 3 months

6. Must have recovered from the acute reversible effects of previous anti-cancer
chemotherapy, endocrine therapy, immunotherapy, radiotherapy or surgery.

- This generally means at least 4 weeks since major surgery, radical radiotherapy
or myelosuppressive chemotherapy (6 weeks for nitrosoureas or mitomycin C).

- At least 4-5 half-lives (t1/2) must have elapsed since treatment with an
investigational agent.

- At least 4 weeks since any hormonal therapy (except LHRH agonists for patients
with HRPC) prior to initiating MT110 treatment.

7. Ability to understand the patient information and informed consent form

8. Signed and dated written informed consent

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

1. Evidence of central nervous system (CNS) metastases on baseline computer tomography
(CT) or magnetic resonance imaging (MRI) scan (mandatory for all patients), current
or past relevant history of other CNS pathology (except migraine, headache and minor
incidental findings in the MRI without any clinical manifestation within the last
five years). All minor incidental findings should be discussed with the Sponsor's
Medical Monitor).

2. Neutrophil count < 1,500/mm3 (= 1.5 x 10^9/l)

3. Platelet count < 100,000/mm3 (= 100 x 10^9/l)

4. White blood cells (WBC) < 3 x10^9/l

5. Hemoglobin < 9.0 g/dl

6. Abnormal renal or hepatic function as defined below:

- Alkaline phosphatase (AP)>/= 2.5 x upper limit of normal (ULN) and/or aspartate
aminotransferase (AST, SGOT), alanin aminotransferase (ALT, SGPT) >/= 2.0 x ULN
or AP, AST and/or ALT >/= 3 x ULN in case of liver metastases; γ-glutamyl
transpeptidase (GGT) >/= 5.0 x ULN

- Total bilirubin >/= 1.5 x ULN

- Creatinine clearance < 50 ml/min calculated by the Cockroft-Gault formula or
MDRD (modification of diet in renal disease)

- Lipase/amylase > 1.5 x ULN

- D-dimer >/= 10 x ULN

- Antithrombin activity < 70%

- International normalized ratio (INR) > ULN

- Partial thromboplastin time (PTT) > ULN

7. Oxygen (O2) saturation of < 92% (under room air condition)

8. Any concurrent anti-neoplastic therapy with the exception of radiotherapy for
palliation of symptoms after agreement by the Sponsor's Medical Monitor. No radiation
is allowed for defined measurable lesions according to RECIST. Patients with HRPC who
have received LHRH-agonist therapy for >1 month, should continue agonist therapy.

9. Any concurrent disease, medical or social condition that could affect compliance with
the protocol or interpretation of results as judged by the investigator. In
particular, patients with the following conditions are not allowed to enter the

- Autoimmune and inflammatory diseases including vasculitis, rheumatoid arthritis,
systemic lupus erythematosus (SLE), multiple sclerosis and similar conditions

- Active infection or known bacteremia

- Known infection with human immunodeficiency virus (HIV) or chronic infection
with hepatitis B virus or hepatitis C virus

- Severe dyspnea or pulmonary dysfunction or need for continuous supportive oxygen

- Insufficient cardiac function defined as NYHA (New York Heart Association) Grade
3 or 4

- History of acute or chronic pancreatitis

10. Chronic systemic corticosteroid therapy longer than 2 months or any other
immunosuppressive therapies or stem-cell transplantation.

11. Presence of human anti-murine antibodies (HAMA) or known hypersensitivity to
immunoglobulins or to other ingredients of the infusion solution.

12. Pregnant, nursing women or women of childbearing potential who are not willing to use
effective forms of contraception during participation in the study and at least three
months thereafter.

13. Male patients with partners of child-bearing potential who are not willing to use
effective contraception during the trial and for at least three months thereafter,
unless surgically sterile.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Amgen Research (Munich) GmbH
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Universitätsklinikum Hamburg-Eppendorf
    • Walter Fiedler, MD, Prof. 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Universitätsklinikum Hamburg-Eppendorf
    • Walter Fiedler, MD, Prof. 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting complete, follow-up complete
  •   2015/01/01
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in and DRKS are not identical. Therefore the data import from required adjustments. For full details please see the DRKS FAQs .
  •   18
  •   2016/01/14

* This entry means the parameter is not applicable or has not been set.